Dr. Hong Discusses IPI-549 in Advanced Solid Tumors

David S. Hong, MD
Published: Friday, Nov 17, 2017



David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses IPI-549 during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

IPI-549 is an oral selective P13K-gamma inhibitor targeting tumor macrophages. Hong presented on the monotherapy dose-escalation clinical and translational data from a first-in-human study of this inhibitor in advanced solid tumors during the meeting.
 


David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses IPI-549 during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

IPI-549 is an oral selective P13K-gamma inhibitor targeting tumor macrophages. Hong presented on the monotherapy dose-escalation clinical and translational data from a first-in-human study of this inhibitor in advanced solid tumors during the meeting.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x